source
- Kura Oncology spins out diabetes program into new company with $50M funding and Lilly supportKura Oncology, known for its leukemia menin inhibitor Komzifti, announced it is separating its diabetes research into a newly formed company. The new entity will receive $50 million in financing,…
- Tyra Biosciences reports Phase 2 success in low-risk bladder cancer, plans pivotal trialTyra Biosciences announced that its experimental therapy for low‑risk bladder cancer has produced encouraging results in a Phase 2 study. The company said the data, released on Wednesday, represen…